ALK and lung cancer: The BRIGHTSTAR (Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Trial) study of local consolidative therapy [7,8] found that anaplastic lymphoma kinase (ALK)–rearranged mutation in advanced NSCLC patients who received targeted therapy for 8 weeks followed by local consolidative therapy prolonged the 3-year progression-free survival (PFS) rate compared to a consolidative therapy group (66% in a brigatinib group vs 47% in a crizotinib group, both with advanced ALK inhibitor–naive, ALK-positive non–small cell lung cancer).